You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 29, 2024

Claims for Patent: 7,834,060


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,834,060
Title:Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphtoic acid for the treatment of dermatological disorders
Abstract:Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions.
Inventor(s): Graeber; Michael (Lawrenceville, NJ), Czernielewski; Janusz (Biot, FR)
Assignee: Galderma Research & Development (Biot, FR)
Application Number:12/437,008
Patent Claims: 1. A method for treating common acne, comedones, polymorphous acne, nodulocystic acne, acne conglobata or secondary acne afflicting the skin of an individual in need of such treatment, comprising topically administering to said individual an effective amount of a pharmaceutical composition which consists essentially of: (a) 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof; (b) one or more ingredients selected from the group consisting of carbomer 940, carbomer 934, propylene glycol, perhydrosqualene, cyclomethicone, PEG-20 methyl glucose sesquistearate and methyl glucose sesquistearate; (c) water; and, (d) optionally, one or more additives selected from the group consisting of wetting agents, pH regulators, osmotic pressure modifiers, emulsifiers, UV-A and UV-B screening agents and antioxidants; said composition being a gel or a cream.

2. The method according to claim 1, wherein said individual is afflicted with common acne.

3. The method according to claim 2, wherein the common acne is of moderate to moderately severe intensity.

4. A method for treating common acne, comedones, polymorphous acne, nodulocystic acne, acne conglobata or secondary acne afflicting the skin of an individual in need of such treatment, comprising topically administering to said individual an effective amount of a pharmaceutical composition which is a gel consisting essentially of 0.3% by weight of adapalene, carbomer 940, disodium edentate, methyl paraben, poloxamer 124, propylene glycol, sodium hydroxide and purified water.

5. The method according to claim 4, wherein said individual is afflicted with common acne.

6. A regime or regimen for treating common acne, comedones, polymorphous acne, nodulocystic acne, acne conglobata or secondary acne afflicting the skin of an individual in need of treatment, comprising topically administering to such individual an effective amount of a pharmaceutical composition which consists essentially of: 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof; one or more ingredients selected from the group consisting of carbomer 940, carbomer 934, propylene glycol, perhydrosqualene, cyclomethicone, PEG-20 methyl glucose sesquistearate, methyl glucose sesquistearate, water, alcohol and polyethylene glycol; and optionally, one or more additives selected from the group consisting of wetting agents, flavor enhancers, preservatives, stabilizers, moisture regulators, pH regulators, osmotic pressure modifiers, emulsifiers, UV-A and UV-B screening agents and antioxidants.

7. The regime or regimen according to claim 6, wherein said individual is afflicted with common acne.

8. The regime or regimen according to claim 7, wherein the common acne is of moderate to moderately severe intensity.

9. The regime or regimen according to claim 6, wherein the composition is a gel.

10. The regime or regimen according to claim 8, wherein the composition is a gel.

11. The regime or regimen according to claim 8, wherein the composition is a gel.

12. A method for treating common acne, comedones, polymorphous acne, nodulocystic acne, acne conglobata or secondary acne afflicting the skin of an individual in need of such treatment, consisting essentially of topically administering to said individual an effective amount of a pharmaceutical composition which consists essentially of: (a) 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof; (b) one or more ingredients selected from the group consisting of carbomer 940, carbomer 934, propylene glycol, perhydrosqualene, cyclomethicone, PEG-20 methyl glucose sesquistearate and methyl glucose sesquistearate; (c) water; and, (d) optionally, one or more additives selected from the group consisting of wetting agents, pH regulators, osmotic pressure modifiers, emulsifiers, UV-A and UV-B screening agents and antioxidants; said composition being a gel or a cream.

13. The method according to claim 12, wherein said individual is afflicted with common acne.

14. The method according to claim 13, wherein the common acne is of moderate to moderately severe intensity.

15. The method according to claim 12, wherein the composition is a gel consisting essentially of adapalene, carbomer 940, disodium edetate, methyl paraben, poloxamer 124, propylene glycol, sodium hydroxide and purified water.

16. The method according to claim 15, wherein said individual is afflicted with common acne.

17. A regime or regimen for treating common acne, comedones, polymorphous acne, nodulocystic acne, acne conglobata or secondary acne afflicting the skin of an individual in need of treatment, consisting essentially of topically administering to such individual an effective amount of a pharmaceutical composition which consists essentially of: 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof; one or more ingredients selected from the group consisting of carbomer 940, carbomer 934, propylene glycol, perhydrosqualene, cyclomethicone, PEG-20 methyl glucose sesquistearate, methyl glucose sesquistearate, water, alcohol and polyethylene glycol; and optionally, one or more additives selected from the group consisting of wetting agents, flavor enhancers, preservatives, stabilizers, moisture regulators, pH regulators, osmotic pressure modifiers, emulsifiers, UV-A and UV-B screening agents and antioxidants.

18. The regime or regimen according to claim 17, wherein said individual is afflicted with common acne.

19. The regime or regimen according to claim 18, wherein the common acne is of moderate to moderately severe intensity.

20. The regime or regimen according to claim 17, wherein the composition is a gel.

21. The regime or regimen according to claim 18, wherein the composition is a gel.

22. The regime or regimen according to claim 19, wherein the composition is a gel.

23. A method for treating common acne, comedones, polymorphous acne, nodulocystic acne, acne conglobata or secondary acne afflicting the skin of an individual in need of such treatment, comprising topically administering to said individual an effective amount of a pharmaceutical composition which comprises 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, as the sole active anti-acne agent, formulated into a pharmaceutically acceptable medium therefor, said composition being a gel or a cream.

24. The method according to claim 23, wherein said individual is afflicted with common acne.

25. The method according to claim 23, wherein the common acne is of moderate to moderately severe intensity.

26. The method according to claim 23, wherein the composition is a gel comprising adapalene, carbomer 940, disodium edetate, methyl paraben, poloxamer 124, propylene glycol, sodium hydroxide and purified water.

27. The method according to claim 24, wherein the composition is a gel comprising adapalene, carbomer 940, disodium edentate, methyl paraben, poloxamer 124, propylene glycol, sodium hydroxide and purified water.

28. A regime or regimen for treating common acne, comedones, polymorphous acne, nodulocystic acne, acne conglobata or secondary acne afflicting the skin of an individual in need of treatment, comprising topically administering to such individual an effective amount of a pharmaceutical composition which comprises 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, as the sole active anti-acne agent, formulated into a pharmaceutically acceptable medium therefor.

29. The regime or regimen according to claim 28, wherein said individual is afflicted with common acne.

30. The regime or regimen according to claim 29, wherein the common acne is of moderate to moderately severe intensity.

31. The regime or regimen according to claim 28, wherein the composition is a gel.

32. The regime or regimen according to claim 29, wherein the composition is a gel.

33. The regime or regimen according to claim 30, wherein the composition is a gel.

34. A method for treating common acne, comedones, polymorphous acne, nodulocystic acne, acne conglobata or secondary acne afflicting the skin of an individual in need of such treatment, comprising topically administering to said individual an effective amount of a pharmaceutical composition which is a gel consisting of 0.3% by weight of adapalene, carbomer 940, disodium edetate, methyl paraben, poloxamer 124, propylene glycol, sodium hydroxide and purified water.

35. The method according to claim 34, wherein said individual is afflicted with common acne.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.